U.S. regulators OK fetal cell transplant

first_img “I’m sure there is no threat to anyone’s identity,” said Arthur Caplan, director of the University of Pennsylvania’s Center for Bioethics. “But we are starting down that road.” What’s more, some of the brain cells to be implanted will be derived from aborted fetuses, which Caplan also said raised ethical concerns for some. Stem Cells Inc., the Palo Alto, Calif. biotechnology company developing the Batten disease treatment, said it receives it fetal tissue from a nonprofit California foundation that also collects tissue from miscarriages and other surgical processes. Stem Cells chief executive Martin McGlynn declined to name the foundation. Stem Cells Inc. first applied for the human test last December, but the FDA demanded more information in February and put the application on hold. An FDA spokeswoman didn’t return telephone calls or an e-mail inquiry. McGlynn said the FDA wanted more information on where the transplanted brain cells were expected to go in the brain and other related health issues such as the chances the transplant might cause tumors. McGlynn also said the agency wanted more information on its manufacturing process and more details about the design of the six-patient test. He said the FDA’s concern was expected. “This endeavor is unique. It’s pioneering and no one has ever proposed to do what we are attempting,” McGlynn said. “Once you put those stem cells in, you can’t get them back.” Stanford University neurosurgeon chief Dr. Stephen Huhn will bore small holes through each child’s skull and inject the neural cells into the patients’ brains. The children will be given drugs to ensure the patients immune system doesn’t attack the new cells and they will be closely monitored for a year. Huhn said the initial Batten trial will primarily test whether the millions of new cells each child receives is safe for them. Ultimately, more tests with many more patients over several years will be needed to determine whether the transplanted cells help Batten patients. 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set! AD Quality Auto 360p 720p 1080p Top articles1/5READ MOREWalnut’s Malik Khouzam voted Southern California Boys Athlete of the Week The stem cells to be transplanted in the brain aren’t human embryonic stem cells, which are derived from days-old embryos. Instead, the cells are immature neural cells that are destined to turn into the mature cells that makeup a fully formed brain. Parkinson’s disease patients and stroke victims have received transplants of fully formed brain cells before, but the malleable brain cells involved here have never before been implanted. Batten disease is caused by a defective gene that fails to create an enzyme needed in the brain to help dispose of brain cellular waste. The waste piles up and kills healthy cells until the patient dies. Most victims die before they reach their teens. The idea is to inject the sick kids with healthy, immature neural stem cells that will “engraft” in a brain that will direct them to turn into cells able to produce the missing enzyme. Such an experiment showed promise in Batten-afflicted mice, but such an ethically charged test has never been tried before in humans. SAN FRANCISCO – Federal regulators on Thursday approved what would be the first transplant of fetal stem cells into human brains, a procedure that if successful could open the door to treating a host of neural disorders. The transplant recipients will be children who suffer from a rare, fatal genetic disorder. The Food and Drug Administration said that doctors at Stanford University Medical Center can begin the testing on six children afflicted with Batten disease, a degenerative malady that renders its young victims blind, speechless and paralyzed before it kills them. An internal Stanford review board must still approve the test, a process that could take weeks. last_img read more